You are here

Press Release Archive

 
- Stephen W. Sanger Elected to Pfizer’s Board of Directors

(BUSINESS WIRE)--Pfizer Inc today announced the election of Stephen W. Sanger to its Board of Directors, effective February 1, 2009. Mr. Sanger, 62, served as the Chairman of General Mills, Inc. from 1995 until his retirement in 2008. He joined General Mills in 1974 and held a variety of positions with increasing responsibility in marketing management across the company's consumer food businesses. He was elected to General Mills

 
- U.S. Patent and Trademark Office Accepts Pfizer’s Reissue Application on Lipitor Enantiomer Patent

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” accepting the company’s application to correct the technical defect in the ‘995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor. The company noted that certain formalities must be completed before the reissue patent will be granted. The reissued patent will have

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the 27th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 9:30 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “27th Annual J.P. Morgan

 
- Bradley E. Lerman Joins Pfizer as Senior Vice President of Litigation

(BUSINESS WIRE)--Pfizer Inc today announced that Bradley E. Lerman will join the company as Senior Vice President, Litigation. Mr. Lerman, who will be responsible for leading the company’s litigation efforts, will report to Senior Vice President and General Counsel Amy W. Schulman. Since 1998, Mr. Lerman has served as a litigation partner at Winston & Strawn LLP in Chicago, where he concentrated his practice in white-

 
- Pfizer Declares a 32-Cent First-Quarter 2009 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent first-quarter 2009 dividend on the company’s common stock, payable March 3, 2009, to shareholders of record at the close of business on February 6, 2009. The first-quarter 2009 cash dividend will be the 281st consecutive quarterly dividend paid by Pfizer.

 
- Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, January 28, 2009. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2008 Performance Report, to be issued that morning To view and listen to the webcast and view the Performance Report, visit

 
- Pfizer Announces Results from Trial of AROMASIN in Postmenopausal Women with Hormone Sensitive Early Breast Cancer

(BUSINESS WIRE)--Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN® (exemestane tablets) vs. tamoxifen. In 2004, based on results of Intergroup Exemestane Study (IES) the TEAM trial design was revised; the tamoxifen arm was converted into a tamoxifen/AROMASIN sequencing

 
- Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria in Africa

(BUSINESS WIRE)--Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, announced today that they have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim®, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.

 
- Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows

(BUSINESS WIRE)--Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of experiencing a cardiovascular event compared with patients taking simvastatin (Zocor®) therapy. The patients in this study did not have evident cardiovascular disease and were newly initiated on either treatment. This study was performed in

 
- Pfizer’s Novel HIV/AIDS Treatment SELZENTRY™ Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients

(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV

 
- Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe

(BUSINESS WIRE)--Pfizer announced today that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from ‘prescription only’ to ‘non-prescription’ in the European Union (EU). Viagra is a well established oral medication for the treatment of erectile dysfunction (ED) and all current doses of Viagra will continue to be available to patients by prescription from their doctor

 
- Pfizer Launches Global Regenerative Medicine Research Unit

(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific progress in understanding the biology of stem cells and the opportunity that provides, to discover and develop a new generation of regenerative medicines for major medical needs. The new unit will announce several significant scientific collaborations in the coming weeks

 
- New Analysis Suggests That Improvements in Kidney Function in Patients Treated with Lipitor Strongly Correlate with a Reduced Risk of Major Cardiovascular Events

(BUSINESS WIRE)--Improvements in kidney function in patients treated with Lipitor® (atorvastatin calcium) were shown to strongly correlate with a reduced risk of major cardiovascular events in patients with pre-existing cardiovascular disease, according to a post hoc sub-analysis of the five-year Treating to New Targets (TNT) study presented today at the Annual Scientific Sessions of the American Heart Association. “This

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jeff Kindler, Chairman and CEO, at the 2008 Credit Suisse Healthcare Conference on Thursday, November 13 at 11:00 a.m. Mountain Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “2008 Credit Suisse Healthcare Conference” link in the Investor

 
- Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)

(BUSINESS WIRE)--Pfizer, Inc announced today that it is terminating the phase 3 development program for its investigational compound (CP-945,598) for weight management. CP-945,598 is a selective antagonist of the cannabinoid type 1 (CB1) receptor. Based on all currently available information and an ongoing review of the phase 3 program by an independent Data Monitoring Committee, Pfizer believes that the CP-945,598 compound has the potential

 
- Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder

(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ™ (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms. New once-daily TOVIAZ can significantly reduce the number of urge urinary incontinence episodes and the frequency of urination over 24 hours, symptoms of OAB that can significantly impact patients’ lives. Overactive bladder

 
- Pfizer's Novel HIV/AIDS Treatment Selzentry(TM) (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naive HIV Patients

(BUSINESS WIRE)--Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES (Reanalysis of the MERIT Study with the Enhanced Trofile Assay) reanalysis presented at the 48th Annual Interscience Conference on Antimicrobial Agents and

 
- Pfizer to Present Data on New Approaches to Pain and Inflammation Treatment at ACR Meeting

(BUSINESS WIRE)--Pfizer will present data on three investigational compounds that represent potential new mechanisms for targeting pain and inflammation. These data will highlight tanezumab, a molecule designed to target nerve growth factor, a key pain mediator; CP-690,550, a JAK-inhibitor that suppresses immune-related inflammatory response; and esreboxetine, a highly-selective norepinephrine reuptake inhibitor which plays a role in

 
- Pfizer Declares a 32-Cent Fourth-Quarter 2008 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent fourth-quarter 2008 dividend on the company’s common stock, payable December 2, 2008, to shareholders of record at the close of business on November 7, 2008. The fourth-quarter 2008 cash dividend will be the 280th consecutive quarterly dividend paid by Pfizer.

 
- Pfizer Completes Settlement Agreements with State Attorneys General Regarding its NSAID Pain Medications

(BUSINESS WIRE)--Pfizer Inc announced today that it has finalized agreements with 33 states and the District of Columbia to resolve claims primarily related to alleged promotional practices for Bextra, a medication Pfizer voluntarily withdrew from the United States market in 2005. Last week Pfizer announced agreements in principle to resolve these state claims, indicating that it would pay $60 million and adopt compliance measures as part of

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.